Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

Blood (2024) 143 (23): 2401–2413.

https://doi.org/10.1182/blood.2023022540

Published: 2024

Includes: Supplemental data

Journal Articles

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2023-172972

Published: 2023

Journal Articles

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Tomomi Toubai, Junya Kuroda, Youko Suehiro, Yuko Mishima, Kazutaka Sunami, Koji Kato, Nobuhiko Uoshima, Takahiro Kumode, Ai Ota, Kaori Mitsuki, Daisuke Yokota, Yuri Sano, Yasuhito Terui

Blood (2023) 142 (Supplement 1): 4464.

https://doi.org/10.1182/blood-2023-179716

Published: 2023

Journal Articles

Survival and CNS Relapse in Patients with CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study in Japan

Blood (2023) 142 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2023-174647

Published: 2023

Journal Articles

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Hang Quach, Gurdeep Parmar, Enrique M. Ocio, H. Miles Prince, Albert Oriol, Nobuhiro Tsukada, Kazutaka Sunami, Pierre Bories, Sumit Madan, Dorothee Semiond, Disa Yu, Sandrine Macé, Florence Suzan, Philippe Moreau

Blood (2022) 140 (Supplement 1): 4412–4414.

https://doi.org/10.1182/blood-2022-166840

Published: 2022

Journal Articles

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Sebastian Grosicki, Ulf-Henrik Mellqvist, Łukasz Pruchniewski, Jacob Crafoord, Suzanne Trudel, Chang-Ki Min, Darrell White, Adrian Alegre, Markus Hansson, Takashi Ikeda, Kazutaka Sunami, Eric Leip, Arthur Kudla, Gregory Finn, Youngil Koh

Blood (2022) 140 (Supplement 1): 4407–4408.

https://doi.org/10.1182/blood-2022-162738

Published: 2022

Journal Articles

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Blood (2022) 140 (Supplement 1): 6421–6423.

https://doi.org/10.1182/blood-2022-157702

Published: 2022

Journal Articles

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 3663–3665.

https://doi.org/10.1182/blood-2022-168696

Published: 2022

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Katja Weisel, MD, George F. Geils, MD, Lionel Karlin, MD, Peter Mollee, FRACP,MBBS,MSc,FRCPA, Tae-Hoon Chung, Chang-Ki Min, MD PhD, Kazutaka Sunami, MD PhD, Amanda Goldrick, MD, Belle Fang, Jessica Fowler, PhD, Maria-Victoria Mateos, MD PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133908

Published: 2020

Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen

Blood (2019) 134 (Supplement_1): 1893.

https://doi.org/10.1182/blood-2019-128010

Published: 2019

Journal Articles

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Hiroshi Handa, MD PhD, Takayuki Saitoh, MD PhD, Kazutaka Sunami, MD PhD, Tadao Ishida, MD PhD, Kenshi Suzuki, MD PhD, Tomoko Narita, MD, Shinsuke Iida, MD PhD, Yuichi Nakamura, MD PhD, Kazuhito Suzuki, MD, Noriko Nishimura, MD PhD, Hirokazu Murakami, MD PhD, Kazuyuki Shimizu, MD

Blood (2019) 134 (Supplement_1): 3085.

https://doi.org/10.1182/blood-2019-125390

Published: 2019

Journal Articles

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Hiroyuki Takamatsu, MD PhD, Shohei Mizuno, MD PhD, Tsutomu Takahashi, MD PhD, Shin-Ichi Fuchida, MD PhD, Ichiro Hanamura, MD PhD, Fumihiko Nakamura, MD PhD, Takehiko Mori, MD PhD, Yuta Katayama, MD PhD, Noriko Doki, MD PhD, Nobuhiro Tsukada, MD PhD, Tatsuo Ichinohe, Yoshinobu Kanda, MD PhD, Yoshiko Atsuta, MD PhD, Kazutaka Sunami, MD PhD

Blood (2019) 134 (Supplement_1): 4358.

https://doi.org/10.1182/blood-2019-123607

Published: 2019

Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD

Blood (2018) 132 (Supplement 1): 3260.

https://doi.org/10.1182/blood-2018-99-116225

Published: 2018

Journal Articles

Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents

Shohei Mizuno, MD PhD, Koji Kawamura, MD PhD, Ichiro Hanamura, MD PhD, Kazutaka Sunami, MD PhD, Takehiko Mori, MD PhD, Fumihiko Nakamura, Shinsuke Iida, MD PhD, Hideyuki Nakazawa, PhD MD, Masanori Makita, Shinichi Kako, MD, Masashi Sawa, MD PhD, Yasunori Ueda, MD PhD, Hiroyuki Takahashi, MD PhD, Yoshinobu Kanda, MD PhD, Tatsuo Ichinohe, MD PhD, Yoshiko Atsuta, MD PhD, Hiroyuki Takamatsu, MD PhD, Akiyoshi Takami, MD

Blood (2018) 132 (Supplement 1): 3437.

https://doi.org/10.1182/blood-2018-99-109905

Published: 2018

Journal Articles

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

Yoshiaki Abe, Yamashita Takeshi, Ueda Mikio, Kazutaka Sunami, MD PhD, Kentaro Narita, MD, Hiroki Kobayashi, MD, Hiroyuki Takamatsu, MD PhD, Akihiro Kitadate, MD PhD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2018) 132 (Supplement 1): 4477.

https://doi.org/10.1182/blood-2018-99-109934

Published: 2018

Journal Articles

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

Blood (2018) 132 (Supplement 1): 5320.

https://doi.org/10.1182/blood-2018-99-111649

Published: 2018

Journal Articles

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Blood (2017) 130 (Supplement 1): 3121.

https://doi.org/10.1182/blood.V130.Suppl_1.3121.3121

Published: 2017

Journal Articles

Dose-Adjusted (DA) - EPOCH-R with High-Dose Methotrexate for Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma (CD5+ DLBCL): Interim Results from a Phase II Study

Blood (2016) 128 (22): 3029.

https://doi.org/10.1182/blood.V128.22.3029.3029

Published: 2016

Journal Articles

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Takayuki Saitoh, MD PhD, Hiroshi Handa, MD PhD, Kenshi Suzuki, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD, Yoshiaki Kuroda, MD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Eiichi Nagura, MD, Shimizu Kazuyuki, MD, Hirokazu Murakami, MD PhD

Blood (2016) 128 (22): 4436.

https://doi.org/10.1182/blood.V128.22.4436.4436

Published: 2016

Journal Articles

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Kazuteru Ohashi, Kenshi Suzuki, MD PhD, Kazutaka Sunami, MD PhD, Shinsuke Iida, MD PhD, Shinichiro Okamoto, MD PhD, Hiroshi Handa, MD PhD, Kosei Matsue, MD PhD, Masafumi Miyoshi, Eric Bleickardt, MD, Morio Matsumoto, MD, Masafumi Taniwaki, MD PhD

Blood (2016) 128 (22): 3315.

https://doi.org/10.1182/blood.V128.22.3315.3315

Published: 2016

NARROW

ctDNA improves prognostic prediction for patients with relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone

CD79 Expression Is Associated with Cell-of-Origin and Outcome in Diffuse Large B-Cell Lymphoma

A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage

Survival and CNS Relapse in Patients with CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study in Japan

Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan

Efficacy and Safety of Zanubrutinib in Japanese Patients with Mature B-Cell Malignancies

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Impact of Continuous and Maintenance Therapy on Survival Outcome in Patients with Newly Diagnosed Multiple Myeloma: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Changing Trends in the Risk Factors of Secondary Primary Malignancies after Autologous Stem Cell Transplantation for Multiple Myeloma before and after the Introduction of Proteasome Inhibitors/Immunomodulatory Agents

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Efficacy and Safety of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma in the Era of Novel Agents

Evaluation of the Revised International Staging System in 400 Patients with Symptomatic Myeloma in a Japanese Clinical Setting

A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Dose-Adjusted (DA) - EPOCH-R with High-Dose Methotrexate for Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma (CD5+ DLBCL): Interim Results from a Phase II Study

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only